Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward

Vaccine

Volumn 33, Issue 50, 2015, Pages 7100-7111

  Guy, Bruno ^a   Briand, Olivier ^a   Lang, Jean ^a   Saville, Melanie ^a   Jackson, Nicholas ^a  

^a SANOFI PASTEUR   (France)

Author keywords

Dengue; Flavivirus; Tetravalent dengue vaccine; Vaccine

Indexed keywords

DENGUE VACCINE; TETRAVALENT DENGUE VACCINE; UNCLASSIFIED DRUG; LIVE VACCINE;

AGE; ARTICLE; DENGUE; DRUG POTENCY; DRUG SAFETY; FLAVIVIRUS; HOST; HUMAN; IMMUNITY; INDUSTRIALIZATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SCALE UP; VACCINATION; ADVERSE DRUG REACTION; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; IMMUNIZATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; PRECLINICAL STUDY; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS AS TOPIC; DENGUE; DENGUE VACCINES; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; IMMUNIZATION SCHEDULE; TREATMENT OUTCOME; VACCINES, ATTENUATED;

EID: 84952639313     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.09.108     Document Type: Article

References (90)

1. Guy B., Guirakhoo F., Barban V., Higgs S., Monath T.P., Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010, 28(3):632-649.
2. Guy B., Barrere B., Malinowski C., Saville M., Teyssou R., Lang J. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011, 29(42):7229-7241.
3. Sabchareon A., Wallace D., Sirivichayakul C., Limkittikul K., Chanthavanich P., Suvannadabba S., et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012, 380(9853):1559-1567.
4. Capeding M.R., Tran N.H., Hadinegoro S.R., Ismail H.I., Chotpitayasunondh T., Chua M.N., et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014, 384(9951):1358-1365.
5. Villar L., Dayan G.H., Arredondo-Garcia J.L., Rivera D.M., Cunha R., Deseda C., et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2015, 372(2):113-123.
6. Thomas S.J. Preventing dengue - is the possibility now a reality?. N Engl J Med 2015, 372(2):172-173.
7. Barban V., Girerd Y., Aguirre M., Gulia S., Petiard F., Riou P., et al. High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production. Vaccine 2007, 25(15):2941-2950.
8. Pugachev K.V., Guirakhoo F., Ocran S.W., Mitchell F., Parsons M., Penal C., et al. High fidelity of yellow fever virus RNA polymerase. J Virol 2004, 78(2):1032-1038.
9. Mantel N., Girerd Y., Geny C., Bernard I., Pontvianne J., Lang J., et al. Genetic stability of a dengue vaccine based on chimeric yellow fever/dengue viruses. Vaccine 2011, 29(38):6629-6635.
10. Dubayle J., Vialle S., Schneider D., Pontvianne J., Mantel N.O.A., et al. Site-specific characterization of envelope protein N-glycosylation on Sanofi Pasteur's tetravalent CYD dengue vaccine. Vaccine 2015, 33(11):1360-1368.
11. Brandler S., Brown N., Ermak T.H., Mitchell F., Parsons M., Zhang Z., et al. Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells. Am J Trop Med Hyg 2005, 72(1):74-81.
12. Deauvieau F., Sanchez V., Balas C., Kennel A., DE Montfort A., Lang J., et al. Innate immune responses in human dendritic cells upon infection by chimeric yellow-fever dengue vaccine serotypes 1-4. Am J Trop Med Hyg 2007, 76(1):144-154.
13. Balas C., Kennel A., Deauvieau F., Sodoyer R., Arnaud-Barbe N., Lang J., et al. Different innate signatures induced in human monocyte-derived dendritic cells by wild-type dengue 3 virus, attenuated but reactogenic dengue 3 vaccine virus, or attenuated nonreactogenic dengue 1-4 vaccine virus strains. J Infect Dis 2011, 203(1):103-108.
14. Guirakhoo F., Weltzin R., Chambers T.J., Zhang Z.X., Soike K., Ratterree M., et al. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 2000, 74(12):5477-5485.
15. Guirakhoo F., Pugachev K., Zhang Z., Myers G., Levenbook I., Draper K., et al. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 2004, 78(9):4761-4775.
16. Guy B., Barban V., Mantel N., Aguirre M., Gulia S., Pontvianne J., et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg 2009, 80(2):302-311.
17. Ravel G., Guy B., Mantel N., Lang J., Gould S. Sanofi Pasteur live attenuated, tetravalent dengue vaccine toxicity, biodistribution and shedding study in cynomolgus monkeys. Abstract 630. Am J Trop Med Hyg 2012, 87(5 Suppl 1):150-226.
18. Higgs S., Vanlandingham D.L., Klingler K.A., McElroy K.L., McGee C.E., Harrington L., et al. Growth characteristics of ChimeriVax-Den vaccine viruses in Aedes aegypti and Aedes albopictus from Thailand. Am J Trop Med Hyg 2006, 75(5):986-993.
19. Kazimirova M., Mantel N., Raynaud S., Slovak M., Ustanikova K., Lang J., et al. Evaluation of chimeric yellow fever 17D/dengue viral replication in ticks. Vector Borne Zoonotic Dis 2012, 12(11):979-985.
20. Monath T.P., Myers G.A., Beck R.A., Knauber M., Scappaticci K., Pullano T., et al. Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: infant mice provide an accurate surrogate for the test in monkeys. Biologicals 2005, 33(3):131-144.
21. McGee C.E., Lewis M.G., Claire M.S., Wagner W., Lang J., Guy B., et al. Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates. J Infect Dis 2008, 197(5):693-697.
22. McGee C.E., Tsetsarkin K., Vanlandingham D.L., McElroy K.L., Lang J., Guy B., et al. Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes. J Infect Dis 2008, 197(5):686-692.
23. McGee C.E., Tsetsarkin K.A., Guy B., Lang J., Plante K., Vanlandingham D.L., et al. Stability of yellow fever virus under recombinatory pressure as compared with chikungunya virus. PLOS ONE 2011, 6(8):e23247.
24. Lefeuvre A. Caractérisation des interactions entre les cellules hépatiques et les souches sauvage et vaccinale du virus de la fièvre jaune: application à l'étude de virus fièvre jaune chimériques utilisés pour le développement d'un vaccin contre la dengue. Diplôme de Doctorat 2005; Université Claude Bernard Lyon 1, No 129 2005.
25. Guy B., Chanthavanich P., Gimenez S., Sirivichayakul C., Sabchareon A., Begue S., et al. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. Vaccine 2004, 22(27-28):3563-3574.
26. Morrison D., Legg T.J., Billings C.W., Forrat R., Yoksan S., Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 2010, 201(3):370-377.
27. Poo J., Galan F., Forrat R., Zambrano B., Lang J., Dayan G.H. Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico city: randomized controlled phase 1 trial of safety and immunogenicity. Pediatr Infect Dis J 2011, 30(1):e9-e17.
28. Capeding R.Z., Luna I.A., Bomasang E., Lupisan S., Lang J., Forrat R., et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine 2011, 29(22):3863-3872.
29. Qiao M., Shaw D., Forrat R., Wartel-Tram A., Lang J. Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans. Am J Trop Med Hyg 2011, 85(4):724-731.
30. Lanata C.F., Andrade T., Gil A.I., Terrones C., Valladolid O., Zambrano B., et al. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru. Vaccine 2012, 30(41):5935-5941.
31. Leo Y.S., Wilder-Smith A., Archuleta S., Shek L.P., Chong C.Y., Leong H.N., et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore. Hum Vaccin Immunother 2012, 8(9):1259-1271.
32. Hss A.S., Koh M.T., Tan K.K., Chan L.G., Zhou L., Bouckenooghe A., et al. Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study. Vaccine 2013, 31(49):5814-5821.
33. Guirakhoo F., Kitchener S., Morrison D., Forrat R., McCarthy K., Nichols R., et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2006, 2(2):60-67.
34. Guy B., Nougarede N., Begue S., Sanchez V., Souag N., Carre M., et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 2008, 26(45):5712-5721.
35. Harenberg A., Begue S., Mamessier A., Gimenez-Fourage S., Ching Seah C., Wei Liang A., et al. Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore. Hum Vaccin Immunother 2013, 9(11):2317-2325.
36. Dayan G., Galán-Herrera G., Forrat R., Zambrano B., Bouckenooghe A., Harenberg A., et al. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico. Hum Vaccin Immunother 2014, 10(10):2853-2863.
37. European Medicines Agency Guideline on quality, non-clinical and clinical aspects of live recombinant viral vectored vaccines. EMA/CHMP/VWP/141697/2009 2010.
38. Monath T.P., Seligman S.J., Robertson J.S., Guy B., Hayes E.B., Condit R.C., et al. Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment. Vaccine 2015, 33(1):62-72.
39. World Health Organization. Guidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated). Geneva: World Health Organization, WHO Expert Committee on Biological Standardization; WHO Technical Report Series, No. 979 Annex 2 (Replacement of Annex 1 of WHO Technical Report Series, No. 932 adopted by ECBS in 2011. 2011. Available at: ). http://www.who.int/biologicals/areas/vaccines/TRS_979_Annex_2pdf?ua=1.
40. Jackson N. Sanofi Pasteur dengue vaccine. The American Society of Tropical Medicine and Hygiene 63rd Annual Meeting, November 3rd Symposium 2014 2014.
41. Hadinegoro S.R., Arredondo-García J.L., Capeding M.R., Deseda C., Chotpitayasunondh T., Dietze R., et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 2015, 373:1195-1206.
42. Gamble J., Bethell D., Day N.P., Loc P.P., Phu N.H., Gartside I.B., et al. Age-related changes in microvascular permeability: a significant factor in the susceptibility of children to shock?. Clin Sci (Lond) 2000, 98(2):211-216.
43. Hanna-Wakim R., Yasukawa L.L., Sung P., Fang M., Sullivan B., Rinki M., et al. Age-related increase in the frequency of CD4(+) T cells that produce interferon-gamma in response to staphylococcal enterotoxin B during childhood. J Infect Dis 2009, 200(12):1921-1927.
44. Jackson N., Boaz M., Hu B., Langevin E., Byers A., Baric R., et al. Investigations of the observed efficacy of the CYD tetravalent dengue vaccine in the phase 2b trial in Ratchaburi, Thailand. Abstract 576. Am J Trop Med Hyg 2014, 91(5 Suppl 1):149-228.
45. Guy B., Boaz M., Byers A., Saulnier A., de Silva A., Henein S., et al. Assessment of the qualitative immune response induced by the CYD tetravalent dengue vaccine in human volunteers. Abstract 575. Am J Trop Med Hyg 2014, 91(5 Suppl 1):149-228.
46. Thomas S.J. Dengue human infection model: re-establishing a tool for understanding dengue immunology and advancing vaccine development. Hum Vaccin Immunother 2013, 9(7):1587-1590.
47. Endy T.P., Nisalak A., Chunsuttitwat S., Vaughn D.W., Green S., Ennis F.A., et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 2004, 189(6):990-1000.
48. Buddhari D., Aldstadt J., Endy T.P., Srikiatkhachorn A., Thaisomboonsuk B., Klungthong C., et al. Dengue virus neutralizing antibody levels associated with protection from infection in thai cluster studies. PLoS Negl Trop Dis 2014, 8(10):e3230.
49. Timiryasova T.M., Bonaparte M.I., Luo P., Zedar R., Hu B.T., Hildreth S.W. Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development. Am J Trop Med Hyg 2013, 88(5):962-970.
50. Rodrigo W.W., Alcena D.C., Rose R.C., Jin X., Schlesinger J.J. An automated Dengue virus microneutralization plaque assay performed in human Fc{gamma} receptor-expressing CV-1 cells. Am J Trop Med Hyg 2009, 80(1):61-65.
51. Putnak J.R., de la Barrera R., Burgess T., Pardo J., Dessy F., Gheysen D., et al. Comparative evaluation of three assays for measurement of dengue virus neutralizing antibodies. Am J Trop Med Hyg 2008, 79(1):115-122.
52. de Alwis R., de Silva A.M. Measuring antibody neutralization of dengue virus (DENV) using a flow cytometry-based technique. Methods Mol Biol 2014, 1138:27-39.
53. Byers A., Broder R., Moser J., Boaz M., Warren W., Jackson N., et al. Serotype-specific dengue neutralizing antibody responses in FcgR expressing CV1 cells. Abstract 833. Am J Trop Med Hyg 2014, 91(5 Suppl 1):228-303.
54. Sabin A.B. Research on dengue during World War II. Am J Trop Med Hyg 1952, 1(1):30-50.
55. Snow G.E., Haaland B., Ooi E.E., Gubler D.J. Review article: research on dengue during World War II revisited. Am J Trop Med Hyg 2014, 91(6):1203-1217.
56. Balmaseda A., Standish K., Mercado J.C., Matute J.C., Tellez Y., Saborio S., et al. Trends in patterns of dengue transmission over 4 years in a pediatric cohort study in Nicaragua. J Infect Dis 2010, 201(1):5-14.
57. Endy T.P., Anderson K.B., Nisalak A., Yoon I.K., Green S., Rothman A.L., et al. Determinants of inapparent and symptomatic dengue infection in a prospective study of primary school children in Kamphaeng Phet, Thailand. PLoS Negl Trop Dis 2011, 5(3):e975.
58. Anderson K.B., Gibbons R.V., Cummings D.A., Nisalak A., Green S., Libraty D.H., et al. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J Infect Dis 2014, 209(3):360-368.
59. Montoya M., Gresh L., Mercado J.C., Williams K.L., Vargas M.J., Gutierrez G., et al. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl Trop Dis 2013, 7(8):e2357.
60. Olkowski S., Forshey B.M., Morrison A.C., Rocha C., Vilcarromero S., Halsey E.S., et al. Reduced risk of disease during postsecondary dengue virus infections. J Infect Dis 2013, 208(6):1026-1033.
61. Mathew A., West K., Kalayanarooj S., Gibbons R.V., Srikiatkhachorn A., Green S., et al. B-cell responses during primary and secondary dengue virus infections in humans. J Infect Dis 2011, 204(10):1514-1522.
62. Lai C.Y., Williams K.L., Wu Y.C., Knight S., Balmaseda A., Harris E., et al. Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases. PLoS Negl Trop Dis 2013, 7(9):e2451.
63. Tsai W.Y., Lai C.Y., Wu Y.C., Lin H.E., Edwards C., Jumnainsong A., et al. High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection. J Virol 2013, 87(23):12562-12575.
64. Patel B., Sapparapu G., Crowe J., Baric R., de Silva A. Characterization of neutralizing antibody responses following natural secondary dengue virus infections. Abstract 626. Am J Trop Med Hyg 2014, 91(5 Suppl 1):149-228.
65. Zompi S., Montoya M., Pohl M.O., Balmaseda A., Harris E. Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans. PLoS Negl Trop Dis 2012, 6(3):e1568.
66. Corbett K.S., Katzelnick L., Tissera H., Amerasinghe A., de Silva A.D., de Silva A.M. Preexisting neutralizing antibody responses distinguish clinically inapparent and apparent dengue virus infections in a Sri Lankan pediatric cohort. J Infect Dis 2015, 211(4):590-599.
67. Anders K.L., Nguyet N.M., Chau N.V., Hung N.T., Thuy T.T., Lien le B., et al. Epidemiological factors associated with dengue shock syndrome and mortality in hospitalized dengue patients in Ho Chi Minh City, Vietnam. Am J Trop Med Hyg 2011, 84(1):127-134.
68. Guzman M.G., Kouri G., Bravo J., Valdes L., Vazquez S., Halstead S.B. Effect of age on outcome of secondary dengue 2 infections. Int J Infect Dis 2002, 6(2):118-124.
69. Hammond S.N., Balmaseda A., Perez L., Tellez Y., Saborio S.I., Mercado J.C., et al. Differences in dengue severity in infants, children, and adults in a 3-year hospital-based study in Nicaragua. Am J Trop Med Hyg 2005, 73(6):1063-1070.
70. Ooi E.E., Goh K.T., Chee Wang D.N. Effect of increasing age on the trend of dengue and dengue hemorrhagic fever in Singapore. Int J Infect Dis 2003, 7(3):231-232.
71. Rothman A.L. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol 2011, 11(8):532-543.
72. Weiskopf D., Angelo M.A., de Azeredo E.L., Sidney J., Greenbaum J.A., Fernando A.N., et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells. Proc Natl Acad Sci U S A 2013, 110(22):E2046-E2053.
73. Zellweger R.M., Eddy W.E., Tang W.W., Miller R., Shresta S. CD8+ T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice. J Immunol 2014, 193(8):4117-4124.
74. Zellweger R.M., Miller R., Eddy W.E., White L.J., Johnston R.E., Shresta S. Role of humoral versus cellular responses induced by a protective dengue vaccine candidate. PLoS Pathog 2013, 9(10):e1003723.
75. Stephens H.A. HLA and other gene associations with dengue disease severity. Curr Top Microbiol Immunol 2010, 338:99-114.
76. Whitehorn J., Chau T.N., Nguyet N.M., Kien D.T., Quyen N.T., Trung D.T., et al. Genetic variants of MICB and PLCE1 and associations with non-severe dengue. PLOS ONE 2013, 8(3):e59067.
77. Barban V., Munoz-Jordan J.L., Santiago G.A., Mantel N., Girerd Y., Gulia S., et al. Broad neutralization of wild-type dengue virus isolates following immunization in monkeys with a tetravalent dengue vaccine based on chimeric yellow fever 17D/dengue viruses. Virology 2012, 429(2):91-98.
78. Dengue and Dengue Hemorrhagic Fever 2014, CABI Publishing, Wallingford, United Kingdom, ISBN-10: 1845939646. 2nd Edition. D.J. Gubler, E.E. Ooi, S. Vasudevan (Eds.).
79. OhAinle M., Balmaseda A., Macalalad A.R., Tellez Y., Zody M.C., Saborio S., et al. Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-specific immunity. Sci Transl Med 2011, 3(114). 114ra128.
80. Barban V., Mantel N., Harenberg A., De Montfort A., Charnay C., Jackson N., et al. Protective immunity induced against DENV-2 intravenous challenge in non-human primates immunized with CYD vaccine clinical lots. Abstract LB-3233. The American Society of Tropical Medicine and Hygiene 63rd Annual Meeting 2014 2014, http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=52126352-c6f3-46f9-9c1f-c18e06fe67c4&cKey=d49492d8-dcd8-4bab-b76b-a1e374fbb4c5&mKey=%7b52AE2426-7F12-4D2B-9404-C0D0B5A8EB5A%7d.
81. de Alwis R., Smith S.A., Olivarez N.P., Messer W.B., Huynh J.P., Wahala W.M., et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A 2012, 109(19):7439-7444.
82. Smith S.A., de Alwis A.R., Kose N., Harris E., Ibarra K.D., Kahle K.M., et al. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. mBio 2013, 4(6). e00873-913.
83. Smith S.A., de Alwis A.R., Kose N., Jadi R.S., de Silva A.M., Crowe J.E. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones. J Virol 2014, 88(21):12233-12241.
84. Dejnirattisai W., Wongwiwat W., Supasa S., Zhang X., Dai X., Rouvinsky A., et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol 2015, 16(2):170-177.
85. Nguyet M.N., Duong T.H., Trung V.T., Nguyen T.H., Tran C.N., Long V.T., et al. Host and viral features of human dengue cases shape the population of infected and infectious Aedes aegypti mosquitoes. Proc Natl Acad Sci U S A 2013, 110(22):9072-9077.
86. Bhatt S., Gething P.W., Brady O.J., Messina J.P., Farlow A.W., Moyes C.L., et al. The global distribution and burden of dengue. Nature 2013, 496(7446):504-507.
87. Guzman M.G., Halstead S.B., Artsob H., Buchy P., Farrar J., Gubler D.J., et al. Dengue: a continuing global threat. Nat Rev Microbiol 2010, 8(12 Suppl):S7-S16.
88. Pulendran B., Li S., Nakaya H.I. Systems vaccinology. Immunity 2010, 33(4):516-529.
89. Malavige G.N., Fernando S., Fernando D.J., Seneviratne S.L. Dengue viral infections. Postgrad Med J 2004, 80:588-601.
90. WHO Dengue guidelines for diagnosis, treatment, prevention and control 2009, http://www.who.int/tdr/publications/documents/dengue-diagnosis.pdf.